For patients with advanced HCC, immunotherapy has emerged as a prospective therapeutic approach through the targeting of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA4) (6). This evidence concerns the gene SNCA and hepatocellular carcinoma.